On Friday, The Food and Drug Administration (FDA) announced it will be taking steps in the coming months to fill gaps in research about the safety and efficacy of CBD. Since hemp and its derivatives, such as cannabidiol, were federally legalized under the 2018 Farm Bill, FDA has been developing regulations for products containing it. However, the agency has taken its time to improve and expand data on the use and effects of CBD. FDA Commissioner Stephen Hahn and Principal Deputy Commissioner Amy Abernethy noted in a new letter, “rapid increase in the interest and availability” of the products but pointed out that “we still have a limited understanding of the safety profile of CBD and many other cannabis-derived compounds, including potential safety risks for people and animals.”
Kyle Jaeger, Marijuana Moment, 01/11/2021 08:37:00